<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01529268</url>
  </required_header>
  <id_info>
    <org_study_id>NASH-CyNCh</org_study_id>
    <secondary_id>U01DK061718</secondary_id>
    <secondary_id>U01DK061728</secondary_id>
    <secondary_id>U01DK061731</secondary_id>
    <secondary_id>U01DK061732</secondary_id>
    <secondary_id>U01DK061734</secondary_id>
    <secondary_id>U01DK061737</secondary_id>
    <secondary_id>U01DK061738</secondary_id>
    <secondary_id>U01DK061730</secondary_id>
    <secondary_id>U01DK061713</secondary_id>
    <nct_id>NCT01529268</nct_id>
  </id_info>
  <brief_title>Cysteamine Bitartrate Delayed-Release for the Treatment of NAFLD in Children</brief_title>
  <acronym>CyNCh</acronym>
  <official_title>Cysteamine Bitartrate Delayed-Release for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Children (CyNCh)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Advancing Translational Science (NCATS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Raptor Pharmaceuticals</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      CyNCh is a multi-center, placebo-controlled clinical trial of children ages 8 to 17 years
      with biopsy-confirmed moderate to severe nonalcoholic fatty liver disease (NAFLD). The
      primary objective is to evaluate whether 52 weeks of treatment with cysteamine bitartrate
      delayed-release capsules will result in improvement in liver disease severity.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in Nonalcoholic Fatty Liver Disease (NAFLD)</measure>
    <time_frame>52 weeks</time_frame>
    <description>Centrally scored and masked assessment of histologic improvement in Nonalcholic Fatty Liver Disease (NAFLD) between the baseline liver biopsy and follow-up biopsy after 52 weeks of treatment, where improvement is defined as: (1) decrease in the NAFLD Activity Score (NAS) of 2 or more and (2) no worsening of fibrosis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Nonalcoholic Fatty Liver Disease (NAFLD) Activity Score (NAS)</measure>
    <time_frame>52 weeks</time_frame>
    <description>Change from baseline in the NAFLD Activity Score (NAS), which is a composite score equal to the sum of the steatosis grade (0-3), lobular inflammation grade (0-3), and hepatocellular ballooning grade (0-2), from centralized pathologist scoring of liver biopsies. The overall scale of the NAS is 0-8, with higher scores indicating more severe disease. The outcome measure, change from baseline in NAFLD Activity Score (NAS), has a possible range from -8 to +8, with negative values indicating a better outcome (improvement) and positive values indicating a worse outcome. Components of the NAS are scored as follows: Steatosis grade 0=&lt;5% steatosis, 1=5-33% steatosis, 2=34-66% steatosis, 3=&gt;66% steatosis. Lobular inflammation grade=amount of lobular inflammation (combines mononuclear, fat granulomas, and polymorphonuclear (pmn) foci): 0=0, 1=&lt;2 under 20x magnification, 2=2-4 under 20x magnification, 3=&gt;4 under 20x magnification. Hepatocellular ballooning 0=none, 1=mild, 2=more than mild.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steatosis: Patients With Improvement</measure>
    <time_frame>52 weeks</time_frame>
    <description>Improvement in steatosis defined as any decrease in steatosis grade comparing 52-week biopsy to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steatosis: Change in Score</measure>
    <time_frame>52 weeks</time_frame>
    <description>Change from baseline in steatosis score. Steatosis score is based on central pathologist grading of liver biopsies: 0=&lt;5% steatosis; 1=5-33% steatosis, 2=34-66% steatosis, 3=&gt;66% steatosis. Change in steatosis score has a possible range of -3 to +3, with negative values indicating a better outcome (improvement) and positive values indicating a worse outcome (no improvement).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lobular Inflammation: Patients With Improvement</measure>
    <time_frame>52 weeks</time_frame>
    <description>Improvement in lobular inflammation defined as any decrease in lobular inflammation grade comparing 52-week biopsy to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lobular Inflammation: Change in Score</measure>
    <time_frame>52 weeks</time_frame>
    <description>Change from baseline in lobular inflammation score. The amount of lobular inflammation is based on central pathologist grading of liver biopsies, and combines mononuclear, fat granulomas, and polymorphonuclear (pmn) foci: 0=none; 1=&lt;2 under 20x magnification, 2=2-4 under 20x magnification, 3=&gt;4 under 20x magnification. Change in lobular inflammation score has a possible range of -3 to +3, with negative values indicating a better outcome (improvement) and positive values indicating a worse outcome (no improvement).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatocellular Ballooning: Patients With Improvement</measure>
    <time_frame>52 weeks</time_frame>
    <description>Improvement in hepatocellular ballooning defined as any decrease in hepatocellular ballooning score comparing 52-week biopsy to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatocellular Ballooning: Change in Score</measure>
    <time_frame>52 weeks</time_frame>
    <description>Change from baseline in hepatocellular ballooning score. The amount of hepatocellular ballooning is based on central pathologist grading of liver biopsies: 0=none; 1=few ballooned hepatocytes, 2=many ballooned hepatocytes. Change in hepatocellular ballooning score has a possible range of -2 to +2, with negative values indicating a better outcome (improvement) and positive values indicating a worse outcome (no improvement).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Portal Inflammation: Patients With Improvement</measure>
    <time_frame>52 weeks</time_frame>
    <description>Improvement in portal inflammation defined as any decrease in portal inflammation score comparing 52-week biopsy to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Portal Inflammation: Change in Score</measure>
    <time_frame>52 weeks</time_frame>
    <description>Change from baseline in portal inflammation score. The amount of portal inflammation is based on central pathologist grading of liver biopsies: 0=none; 1=mild, 2=more than mild. Change in portal inflammation score has a possible range of -2 to +2, with negative values indicating a better outcome (improvement) and positive values indicating a worse outcome (no improvement).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrosis: Patients With Improvement</measure>
    <time_frame>52 weeks</time_frame>
    <description>Improvement in fibrosis stage defined as any decrease in fibrosis stage comparing 52-week biopsy to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrosis: Change in Stage</measure>
    <time_frame>52 weeks</time_frame>
    <description>Change from baseline in fibrosis stage. The amount of fibrosis is based on central pathologist grading of liver biopsies: 0=none; 1a=mild, zone 3 perisinusoidal, 1b=moderate, zone 3, perisinusoidal, 1c=portal/periportal only, 2=zone 3 and periportal, any combination, 3=bridging, 4=cirrhosis. Fibrosis stages 1a, 1b, 1c recoded as 1, so the possible range of values for fibrosis stage was 0-4. Change in fibrosis stage has a possible range of -4 to +4, with negative values indicating a better outcome (improvement) and positive values indicating a worse outcome (no improvement).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resolution of NASH</measure>
    <time_frame>52 weeks</time_frame>
    <description>Patients with a change from a histological diagnosis of definite NASH or indeterminate for NASH to not NASH at end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Aminotransferase and Gamma-glutamyl Transpeptidase</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Weight (kg)</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body-mass Index</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body-mass Index Z-score</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Waist Circumference</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Serum Glucose</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Insulin</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HOMA-IR</measure>
    <time_frame>52 weeks</time_frame>
    <description>(Glucose (mmol/L) x insulin (pmol/L))/22.5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Systolic Blood Pressure</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Diastolic Blood Pressure</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pediatric Quality of Life Inventory (PedsQL) Score</measure>
    <time_frame>52 weeks</time_frame>
    <description>Pediatric Quality of Life Inventory (PedsQL) version 4.0 is completed by both the child and parent/caregiver, and is composed of 23 items comprising 4 dimensions: Physical Functioning, Emotional Functioning, Social Functioning, and School Functioning. Scores are transformed on a scale from 0 to 100, with higher scores indicating better health-related quality of life. Physical Health Summary Score =Physical Functioning Scale Score. Psychosocial Health Summary Score = Sum of items over the number of items answered in the Emotional, Social, and School Functioning Scales.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in MRI-determined Hepatic Fat Fraction</measure>
    <time_frame>52 weeks</time_frame>
    <description>Change from baseline in MRI Proton Density Fat Fraction (PDFF) (%).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">169</enrollment>
  <condition>Nonalcoholic Fatty Liver Disease (NAFLD)</condition>
  <arm_group>
    <arm_group_label>DR cysteamine bitartrate capsule</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active DR cysteamine bitartrate capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DR cysteamine bitartrate placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo DR cysteamine bitartrate capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DR cysteamine bitartrate capsule</intervention_name>
    <description>600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline
750 mg/day (five 75 mg capsules twice daily) for patients &gt;65 - 80 kg at baseline
900 mg/day (six 75 mg capsules twice daily) for patients &gt;80 kg at baseline</description>
    <arm_group_label>DR cysteamine bitartrate capsule</arm_group_label>
    <other_name>cysteamine bitartrate delayed-release</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>DR cysteamine bitartrate placebo</intervention_name>
    <description>600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline
750 mg/day (five 75 mg capsules twice daily) for patients &gt;65 - 80 kg at baseline
900 mg/day (six 75 mg capsules twice daily) for patients &gt;80 kg at baseline</description>
    <arm_group_label>DR cysteamine bitartrate placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children age 8-17 years

          -  Liver biopsy obtained within 90 days of screening visit and not more than 120 days
             before randomization

          -  Clinical history consistent with nonalcoholic fatty liver disease (NAFLD)

          -  Definite NAFLD based upon liver histology

          -  No evidence of any other liver disease by clinical history or histological evaluation

          -  A histological severity of: NAFLD Activity Score (NAS) ≥ 4.

          -  Sexually active female participants of childbearing potential (i.e., not surgically
             sterile [defined as tubal ligation, hysterectomy, or bilateral oophorectomy]) must
             agree to utilize the same two acceptable forms of contraception from screening through
             completion of the study and to complete a serum pregnancy test at each study visit.
             The acceptable forms of contraception for this study include hormonal contraceptives
             (oral, implant, transdermal patch, or injection) at a stable dose for at least 3
             months prior to screening, and barrier (condom with spermicide, diaphragm with
             spermicide). Sexual activity will be ascertained at each study visit for
             post-menarchal females and if sexually active, subject must verify use of the same 2
             acceptable forms of contraception. For pre-pubescent children, a documented
             attestation of abstinence from their parent or guardian will be acceptable.

          -  Participants must be able to swallow DR Cysteamine tablets with the tablet intact

          -  Written informed consent from parent or legal guardian

          -  Written informed assent from the child

        Exclusion Criteria:

          -  There will be no exclusion criteria based on race, ethnicity or gender.

          -  Participants with a current history of the following conditions or any other health
             issues that make it unsafe for them to participate in the opinion of the
             Investigators:

               -  Inflammatory bowel disease (if currently active) or prior resection of small
                  intestine

               -  Heart disease (e.g., myocardial infarction, heart failure, unstable arrhythmias)

               -  Seizure disorder

               -  Active coagulopathy

               -  Gastrointestinal ulcers/bleeding

               -  Renal dysfunction with a creatinine clearance &lt; 90 mL/min/m2

               -  History of active malignant disease requiring chemotherapy within the past 12
                  months prior to randomization

               -  History of significant alcohol intake (AUDIT questionnaire) or inability to
                  quantify alcohol consumption

               -  Chronic use (more than 2 consecutive weeks) of medications known to cause hepatic
                  steatosis or steatohepatitis (systemic glucocorticoids, tetracycline, anabolic
                  steroids, valproic acid, salicylates, tamoxifen) in the past year.

               -  The use of other known hepatotoxins within 90 days of liver biopsy or within 120
                  days of randomization

               -  Initiation of medications with the intent to treat NAFLD/NASH in the time period
                  following liver biopsy and prior to randomization

               -  History of total parenteral nutrition (TPN) use in year prior to screening

               -  History of bariatric surgery or planning to undergo bariatric surgery during
                  study duration

               -  Clinically significant depression (patients hospitalized for suicidal ideations
                  or suicide attempts within the past 12 months)

               -  Any female nursing, planning a pregnancy, known or suspected to be pregnant, or
                  who has a positive serum pregnancy screen.

          -  Non-compensated liver disease with any one of the following hematologic, biochemical,
             and serological criteria on entry into protocol:

               -  Hemoglobin &lt; 10 g/dL;

               -  White blood cell (WBC) &lt; 3,500 cells/mm3 of blood;

               -  Neutrophil count &lt; 1,500 cells/mm3 of blood;

               -  Platelets &lt; 130,000 cells/mm3 of blood;

               -  Direct bilirubin &gt; 1.0 mg/dL

               -  Total bilirubin &gt;3 mg/dL

               -  Albumin &lt; 3.2 g/dL

               -  International normalized ratio (INR) &gt; 1.4

          -  Poorly controlled diabetes mellitus (hemoglobin A1c (HbA1c) &gt; 9%)

          -  Evidence of other chronic liver disease:

               -  Biopsy consistent with histological evidence of autoimmune hepatitis

               -  Serum hepatitis B surface antigen (HBsAg) positive.

               -  Serum hepatitis C antibody (anti-HCV) positive.

               -  Iron/total iron binding capacity (TIBC) ratio (transferrin saturation) &gt; 45% with
                  histological evidence of iron overload

               -  Alpha-1-antitrypsin (A1AT) phenotype ZZ or SZ

               -  Wilson's disease

          -  Children who are currently enrolled in a clinical trial or who received an
             investigational study drug within 180 days of screening or liver biopsy.

          -  Subjects who are not able or willing to comply with the protocol or have any other
             condition that would impede compliance or hinder completion of the study, in the
             opinion of the investigator.

          -  Failure to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward Doo, MD</last_name>
    <role>Study Director</role>
    <affiliation>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital of Chicago (NWU)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-2605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington, Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://jhuccs1.us/nash/open/centers/centers.htm</url>
    <description>Nonalcoholic Steatohepatitis Clinical Research Network Centers</description>
  </link>
  <link>
    <url>http://www2.niddk.nih.gov/</url>
    <description>The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</description>
  </link>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2012</study_first_submitted>
  <study_first_submitted_qc>February 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2012</study_first_posted>
  <results_first_submitted>April 10, 2017</results_first_submitted>
  <results_first_submitted_qc>August 2, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">September 5, 2017</results_first_posted>
  <last_update_submitted>August 2, 2017</last_update_submitted>
  <last_update_submitted_qc>August 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nonalcoholic Fatty Liver Disease (NAFLD)</keyword>
  <keyword>Cysteamine bitartrate delayed release</keyword>
  <keyword>Children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cysteamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Public use database deposited with the NIDDK Central Repository</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were enrolled at 10 NASH CRN clinical centers from June 2012 to January 2014.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>DR Cysteamine Bitartrate Capsule</title>
          <description>Active DR cysteamine bitartrate capsule
DR cysteamine bitartrate capsule: ◦ 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline
750 mg/day (five 75 mg capsules twice daily) for patients &gt;65 - 80 kg at baseline
900 mg/day (six 75 mg capsules twice daily) for patients &gt;80 kg at baseline</description>
        </group>
        <group group_id="P2">
          <title>DR Cysteamine Bitartrate Placebo</title>
          <description>Placebo DR cysteamine bitartrate capsule
DR cysteamine bitartrate placebo: ◦ 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline
750 mg/day (five 75 mg capsules twice daily) for patients &gt;65 - 80 kg at baseline
900 mg/day (six 75 mg capsules twice daily) for patients &gt;80 kg at baseline</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="88"/>
                <participants group_id="P2" count="81"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed 52-week Biopsy</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="78"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Moved</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>DR Cysteamine Bitartrate Capsule</title>
          <description>Active DR cysteamine bitartrate capsule
DR cysteamine bitartrate capsule: ◦ 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline
750 mg/day (five 75 mg capsules twice daily) for patients &gt;65 - 80 kg at baseline
900 mg/day (six 75 mg capsules twice daily) for patients &gt;80 kg at baseline</description>
        </group>
        <group group_id="B2">
          <title>DR Cysteamine Bitartrate Placebo</title>
          <description>Placebo DR cysteamine bitartrate capsule
DR cysteamine bitartrate placebo: ◦ 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline
750 mg/day (five 75 mg capsules twice daily) for patients &gt;65 - 80 kg at baseline
900 mg/day (six 75 mg capsules twice daily) for patients &gt;80 kg at baseline</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="88"/>
            <count group_id="B2" value="81"/>
            <count group_id="B3" value="169"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.8" spread="2.9"/>
                    <measurement group_id="B2" value="13.6" spread="2.5"/>
                    <measurement group_id="B3" value="13.7" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian/Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African-American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Refusal/not stated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alanine aminotransferase</title>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="140" spread="118"/>
                    <measurement group_id="B2" value="103" spread="76"/>
                    <measurement group_id="B3" value="123" spread="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Aspartate aminotransferase</title>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82" spread="71"/>
                    <measurement group_id="B2" value="59" spread="38"/>
                    <measurement group_id="B3" value="71" spread="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight group</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Less than or equal to 65 kg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;65-80 kg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;80 kg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Improvement in Nonalcoholic Fatty Liver Disease (NAFLD)</title>
        <description>Centrally scored and masked assessment of histologic improvement in Nonalcholic Fatty Liver Disease (NAFLD) between the baseline liver biopsy and follow-up biopsy after 52 weeks of treatment, where improvement is defined as: (1) decrease in the NAFLD Activity Score (NAS) of 2 or more and (2) no worsening of fibrosis.</description>
        <time_frame>52 weeks</time_frame>
        <population>Analysis based on intention to treat; patients with missing 52-week biopsy were imputed as lack of improvement.</population>
        <group_list>
          <group group_id="O1">
            <title>DR Cysteamine Bitartrate Capsule</title>
            <description>Active DR cysteamine bitartrate capsule
DR cysteamine bitartrate capsule: ◦ 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline
750 mg/day (five 75 mg capsules twice daily) for patients &gt;65 - 80 kg at baseline
900 mg/day (six 75 mg capsules twice daily) for patients &gt;80 kg at baseline</description>
          </group>
          <group group_id="O2">
            <title>DR Cysteamine Bitartrate Placebo</title>
            <description>Placebo DR cysteamine bitartrate capsule
DR cysteamine bitartrate placebo: ◦ 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline
750 mg/day (five 75 mg capsules twice daily) for patients &gt;65 - 80 kg at baseline
900 mg/day (six 75 mg capsules twice daily) for patients &gt;80 kg at baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Improvement in Nonalcoholic Fatty Liver Disease (NAFLD)</title>
          <description>Centrally scored and masked assessment of histologic improvement in Nonalcholic Fatty Liver Disease (NAFLD) between the baseline liver biopsy and follow-up biopsy after 52 weeks of treatment, where improvement is defined as: (1) decrease in the NAFLD Activity Score (NAS) of 2 or more and (2) no worsening of fibrosis.</description>
          <population>Analysis based on intention to treat; patients with missing 52-week biopsy were imputed as lack of improvement.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Relative risks and p-values were calculated with the Cochran-Mantel-Haenszel chi-square tests, stratified by clinic and weight group, for binary outcomes.</non_inferiority_desc>
            <p_value>0.34</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8</ci_lower_limit>
            <ci_upper_limit>2.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Nonalcoholic Fatty Liver Disease (NAFLD) Activity Score (NAS)</title>
        <description>Change from baseline in the NAFLD Activity Score (NAS), which is a composite score equal to the sum of the steatosis grade (0-3), lobular inflammation grade (0-3), and hepatocellular ballooning grade (0-2), from centralized pathologist scoring of liver biopsies. The overall scale of the NAS is 0-8, with higher scores indicating more severe disease. The outcome measure, change from baseline in NAFLD Activity Score (NAS), has a possible range from -8 to +8, with negative values indicating a better outcome (improvement) and positive values indicating a worse outcome. Components of the NAS are scored as follows: Steatosis grade 0=&lt;5% steatosis, 1=5-33% steatosis, 2=34-66% steatosis, 3=&gt;66% steatosis. Lobular inflammation grade=amount of lobular inflammation (combines mononuclear, fat granulomas, and polymorphonuclear (pmn) foci): 0=0, 1=&lt;2 under 20x magnification, 2=2-4 under 20x magnification, 3=&gt;4 under 20x magnification. Hepatocellular ballooning 0=none, 1=mild, 2=more than mild.</description>
        <time_frame>52 weeks</time_frame>
        <population>The smaller number of participants analyzed is due to missing 52-week biopsies (complete case analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>DR Cysteamine Bitartrate Capsule</title>
            <description>Active DR cysteamine bitartrate capsule
DR cysteamine bitartrate capsule: ◦ 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline
750 mg/day (five 75 mg capsules twice daily) for patients &gt;65 - 80 kg at baseline
900 mg/day (six 75 mg capsules twice daily) for patients &gt;80 kg at baseline</description>
          </group>
          <group group_id="O2">
            <title>DR Cysteamine Bitartrate Placebo</title>
            <description>Placebo DR cysteamine bitartrate capsule
DR cysteamine bitartrate placebo: ◦ 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline
750 mg/day (five 75 mg capsules twice daily) for patients &gt;65 - 80 kg at baseline
900 mg/day (six 75 mg capsules twice daily) for patients &gt;80 kg at baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Nonalcoholic Fatty Liver Disease (NAFLD) Activity Score (NAS)</title>
          <description>Change from baseline in the NAFLD Activity Score (NAS), which is a composite score equal to the sum of the steatosis grade (0-3), lobular inflammation grade (0-3), and hepatocellular ballooning grade (0-2), from centralized pathologist scoring of liver biopsies. The overall scale of the NAS is 0-8, with higher scores indicating more severe disease. The outcome measure, change from baseline in NAFLD Activity Score (NAS), has a possible range from -8 to +8, with negative values indicating a better outcome (improvement) and positive values indicating a worse outcome. Components of the NAS are scored as follows: Steatosis grade 0=&lt;5% steatosis, 1=5-33% steatosis, 2=34-66% steatosis, 3=&gt;66% steatosis. Lobular inflammation grade=amount of lobular inflammation (combines mononuclear, fat granulomas, and polymorphonuclear (pmn) foci): 0=0, 1=&lt;2 under 20x magnification, 2=2-4 under 20x magnification, 3=&gt;4 under 20x magnification. Hepatocellular ballooning 0=none, 1=mild, 2=more than mild.</description>
          <population>The smaller number of participants analyzed is due to missing 52-week biopsies (complete case analysis).</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="1.8"/>
                    <measurement group_id="O2" value="-0.8" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>P-values and mean changes from baseline were calculated using ANCOVA, regressing change from baseline to 52 weeks on treatment group and baseline value of the outcome, for outcome scores.</non_inferiority_desc>
            <p_value>0.90</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>0.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Steatosis: Patients With Improvement</title>
        <description>Improvement in steatosis defined as any decrease in steatosis grade comparing 52-week biopsy to baseline.</description>
        <time_frame>52 weeks</time_frame>
        <population>Analysis based on intention to treat; patients with missing 52-week biopsy were imputed as lack of improvement.</population>
        <group_list>
          <group group_id="O1">
            <title>DR Cysteamine Bitartrate Capsule</title>
            <description>Active DR cysteamine bitartrate capsule
DR cysteamine bitartrate capsule: ◦ 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline
750 mg/day (five 75 mg capsules twice daily) for patients &gt;65 - 80 kg at baseline
900 mg/day (six 75 mg capsules twice daily) for patients &gt;80 kg at baseline</description>
          </group>
          <group group_id="O2">
            <title>DR Cysteamine Bitartrate Placebo</title>
            <description>Placebo DR cysteamine bitartrate capsule
DR cysteamine bitartrate placebo: ◦ 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline
750 mg/day (five 75 mg capsules twice daily) for patients &gt;65 - 80 kg at baseline
900 mg/day (six 75 mg capsules twice daily) for patients &gt;80 kg at baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Steatosis: Patients With Improvement</title>
          <description>Improvement in steatosis defined as any decrease in steatosis grade comparing 52-week biopsy to baseline.</description>
          <population>Analysis based on intention to treat; patients with missing 52-week biopsy were imputed as lack of improvement.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Steatosis: patients with improvement</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Relative risks and p-values were calculated with the Cochran-Mantel-Haenszel chi-square tests, stratified by clinic and weight group, for binary outcomes.</non_inferiority_desc>
            <p_value>0.15</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.5</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Steatosis: Change in Score</title>
        <description>Change from baseline in steatosis score. Steatosis score is based on central pathologist grading of liver biopsies: 0=&lt;5% steatosis; 1=5-33% steatosis, 2=34-66% steatosis, 3=&gt;66% steatosis. Change in steatosis score has a possible range of -3 to +3, with negative values indicating a better outcome (improvement) and positive values indicating a worse outcome (no improvement).</description>
        <time_frame>52 weeks</time_frame>
        <population>The smaller number of participants analyzed is due to missing 52-week biopsies (complete case analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>DR Cysteamine Bitartrate Capsule</title>
            <description>Active DR cysteamine bitartrate capsule
DR cysteamine bitartrate capsule: ◦ 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline
750 mg/day (five 75 mg capsules twice daily) for patients &gt;65 - 80 kg at baseline
900 mg/day (six 75 mg capsules twice daily) for patients &gt;80 kg at baseline</description>
          </group>
          <group group_id="O2">
            <title>DR Cysteamine Bitartrate Placebo</title>
            <description>Placebo DR cysteamine bitartrate capsule
DR cysteamine bitartrate placebo: ◦ 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline
750 mg/day (five 75 mg capsules twice daily) for patients &gt;65 - 80 kg at baseline
900 mg/day (six 75 mg capsules twice daily) for patients &gt;80 kg at baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Steatosis: Change in Score</title>
          <description>Change from baseline in steatosis score. Steatosis score is based on central pathologist grading of liver biopsies: 0=&lt;5% steatosis; 1=5-33% steatosis, 2=34-66% steatosis, 3=&gt;66% steatosis. Change in steatosis score has a possible range of -3 to +3, with negative values indicating a better outcome (improvement) and positive values indicating a worse outcome (no improvement).</description>
          <population>The smaller number of participants analyzed is due to missing 52-week biopsies (complete case analysis).</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.9"/>
                    <measurement group_id="O2" value="-0.4" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Steatosis: change in score</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>P-values and mean changes from baseline were calculated using ANCOVA, regressing change from baseline to 52 weeks on treatment group and baseline value of the outcome, for outcome scores.</non_inferiority_desc>
            <p_value>0.59</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2</ci_lower_limit>
            <ci_upper_limit>0.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lobular Inflammation: Patients With Improvement</title>
        <description>Improvement in lobular inflammation defined as any decrease in lobular inflammation grade comparing 52-week biopsy to baseline.</description>
        <time_frame>52 weeks</time_frame>
        <population>Analysis based on intention to treat; patients with missing 52-week biopsy were imputed as lack of improvement.</population>
        <group_list>
          <group group_id="O1">
            <title>DR Cysteamine Bitartrate Capsule</title>
            <description>Active DR cysteamine bitartrate capsule
DR cysteamine bitartrate capsule: ◦ 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline
750 mg/day (five 75 mg capsules twice daily) for patients &gt;65 - 80 kg at baseline
900 mg/day (six 75 mg capsules twice daily) for patients &gt;80 kg at baseline</description>
          </group>
          <group group_id="O2">
            <title>DR Cysteamine Bitartrate Placebo</title>
            <description>Placebo DR cysteamine bitartrate capsule
DR cysteamine bitartrate placebo: ◦ 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline
750 mg/day (five 75 mg capsules twice daily) for patients &gt;65 - 80 kg at baseline
900 mg/day (six 75 mg capsules twice daily) for patients &gt;80 kg at baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Lobular Inflammation: Patients With Improvement</title>
          <description>Improvement in lobular inflammation defined as any decrease in lobular inflammation grade comparing 52-week biopsy to baseline.</description>
          <population>Analysis based on intention to treat; patients with missing 52-week biopsy were imputed as lack of improvement.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Relative risks and p-values were calculated with the Cochran-Mantel-Haenszel chi-square tests, stratified by clinic and weight group, for binary outcomes.</non_inferiority_desc>
            <p_value>0.03</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.1</ci_lower_limit>
            <ci_upper_limit>2.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lobular Inflammation: Change in Score</title>
        <description>Change from baseline in lobular inflammation score. The amount of lobular inflammation is based on central pathologist grading of liver biopsies, and combines mononuclear, fat granulomas, and polymorphonuclear (pmn) foci: 0=none; 1=&lt;2 under 20x magnification, 2=2-4 under 20x magnification, 3=&gt;4 under 20x magnification. Change in lobular inflammation score has a possible range of -3 to +3, with negative values indicating a better outcome (improvement) and positive values indicating a worse outcome (no improvement).</description>
        <time_frame>52 weeks</time_frame>
        <population>The smaller number of participants analyzed is due to missing 52-week biopsies (complete case analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>DR Cysteamine Bitartrate Capsule</title>
            <description>Active DR cysteamine bitartrate capsule
DR cysteamine bitartrate capsule: ◦ 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline
750 mg/day (five 75 mg capsules twice daily) for patients &gt;65 - 80 kg at baseline
900 mg/day (six 75 mg capsules twice daily) for patients &gt;80 kg at baseline</description>
          </group>
          <group group_id="O2">
            <title>DR Cysteamine Bitartrate Placebo</title>
            <description>Placebo DR cysteamine bitartrate capsule
DR cysteamine bitartrate placebo: ◦ 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline
750 mg/day (five 75 mg capsules twice daily) for patients &gt;65 - 80 kg at baseline
900 mg/day (six 75 mg capsules twice daily) for patients &gt;80 kg at baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Lobular Inflammation: Change in Score</title>
          <description>Change from baseline in lobular inflammation score. The amount of lobular inflammation is based on central pathologist grading of liver biopsies, and combines mononuclear, fat granulomas, and polymorphonuclear (pmn) foci: 0=none; 1=&lt;2 under 20x magnification, 2=2-4 under 20x magnification, 3=&gt;4 under 20x magnification. Change in lobular inflammation score has a possible range of -3 to +3, with negative values indicating a better outcome (improvement) and positive values indicating a worse outcome (no improvement).</description>
          <population>The smaller number of participants analyzed is due to missing 52-week biopsies (complete case analysis).</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="0.8"/>
                    <measurement group_id="O2" value="-0.1" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>P-values and mean changes from baseline were calculated using ANCOVA, regressing change from baseline to 52 weeks on treatment group and baseline value of the outcome, for outcome scores.</non_inferiority_desc>
            <p_value>0.06</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>0.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hepatocellular Ballooning: Patients With Improvement</title>
        <description>Improvement in hepatocellular ballooning defined as any decrease in hepatocellular ballooning score comparing 52-week biopsy to baseline.</description>
        <time_frame>52 weeks</time_frame>
        <population>Analysis based on intention to treat; patients with missing 52-week biopsy were imputed as lack of improvement.</population>
        <group_list>
          <group group_id="O1">
            <title>DR Cysteamine Bitartrate Capsule</title>
            <description>Active DR cysteamine bitartrate capsule
DR cysteamine bitartrate capsule: ◦ 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline
750 mg/day (five 75 mg capsules twice daily) for patients &gt;65 - 80 kg at baseline
900 mg/day (six 75 mg capsules twice daily) for patients &gt;80 kg at baseline</description>
          </group>
          <group group_id="O2">
            <title>DR Cysteamine Bitartrate Placebo</title>
            <description>Placebo DR cysteamine bitartrate capsule
DR cysteamine bitartrate placebo: ◦ 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline
750 mg/day (five 75 mg capsules twice daily) for patients &gt;65 - 80 kg at baseline
900 mg/day (six 75 mg capsules twice daily) for patients &gt;80 kg at baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Hepatocellular Ballooning: Patients With Improvement</title>
          <description>Improvement in hepatocellular ballooning defined as any decrease in hepatocellular ballooning score comparing 52-week biopsy to baseline.</description>
          <population>Analysis based on intention to treat; patients with missing 52-week biopsy were imputed as lack of improvement.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Relative risks and p-values were calculated with the Cochran-Mantel-Haenszel chi-square tests, stratified by clinic and weight group, for binary outcomes.</non_inferiority_desc>
            <p_value>0.29</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.4</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hepatocellular Ballooning: Change in Score</title>
        <description>Change from baseline in hepatocellular ballooning score. The amount of hepatocellular ballooning is based on central pathologist grading of liver biopsies: 0=none; 1=few ballooned hepatocytes, 2=many ballooned hepatocytes. Change in hepatocellular ballooning score has a possible range of -2 to +2, with negative values indicating a better outcome (improvement) and positive values indicating a worse outcome (no improvement).</description>
        <time_frame>52 weeks</time_frame>
        <population>The smaller number of participants analyzed is due to missing 52-week biopsies (complete case analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>DR Cysteamine Bitartrate Capsule</title>
            <description>Active DR cysteamine bitartrate capsule
DR cysteamine bitartrate capsule: ◦ 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline
750 mg/day (five 75 mg capsules twice daily) for patients &gt;65 - 80 kg at baseline
900 mg/day (six 75 mg capsules twice daily) for patients &gt;80 kg at baseline</description>
          </group>
          <group group_id="O2">
            <title>DR Cysteamine Bitartrate Placebo</title>
            <description>Placebo DR cysteamine bitartrate capsule
DR cysteamine bitartrate placebo: ◦ 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline
750 mg/day (five 75 mg capsules twice daily) for patients &gt;65 - 80 kg at baseline
900 mg/day (six 75 mg capsules twice daily) for patients &gt;80 kg at baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Hepatocellular Ballooning: Change in Score</title>
          <description>Change from baseline in hepatocellular ballooning score. The amount of hepatocellular ballooning is based on central pathologist grading of liver biopsies: 0=none; 1=few ballooned hepatocytes, 2=many ballooned hepatocytes. Change in hepatocellular ballooning score has a possible range of -2 to +2, with negative values indicating a better outcome (improvement) and positive values indicating a worse outcome (no improvement).</description>
          <population>The smaller number of participants analyzed is due to missing 52-week biopsies (complete case analysis).</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.7"/>
                    <measurement group_id="O2" value="-0.3" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>P-values and mean changes from baseline were calculated using ANCOVA, regressing change from baseline to 52 weeks on treatment group and baseline value of the outcome, for outcome scores.</non_inferiority_desc>
            <p_value>0.15</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1</ci_lower_limit>
            <ci_upper_limit>0.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Portal Inflammation: Patients With Improvement</title>
        <description>Improvement in portal inflammation defined as any decrease in portal inflammation score comparing 52-week biopsy to baseline.</description>
        <time_frame>52 weeks</time_frame>
        <population>Analysis based on intention to treat; patients with missing 52-week biopsy were imputed as lack of improvement.</population>
        <group_list>
          <group group_id="O1">
            <title>DR Cysteamine Bitartrate Capsule</title>
            <description>Active DR cysteamine bitartrate capsule
DR cysteamine bitartrate capsule: ◦ 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline
750 mg/day (five 75 mg capsules twice daily) for patients &gt;65 - 80 kg at baseline
900 mg/day (six 75 mg capsules twice daily) for patients &gt;80 kg at baseline</description>
          </group>
          <group group_id="O2">
            <title>DR Cysteamine Bitartrate Placebo</title>
            <description>Placebo DR cysteamine bitartrate capsule
DR cysteamine bitartrate placebo: ◦ 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline
750 mg/day (five 75 mg capsules twice daily) for patients &gt;65 - 80 kg at baseline
900 mg/day (six 75 mg capsules twice daily) for patients &gt;80 kg at baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Portal Inflammation: Patients With Improvement</title>
          <description>Improvement in portal inflammation defined as any decrease in portal inflammation score comparing 52-week biopsy to baseline.</description>
          <population>Analysis based on intention to treat; patients with missing 52-week biopsy were imputed as lack of improvement.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Relative risks and p-values were calculated with the Cochran-Mantel-Haenszel chi-square tests, stratified by clinic and weight group, for binary outcomes.</non_inferiority_desc>
            <p_value>0.57</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.6</ci_lower_limit>
            <ci_upper_limit>2.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Portal Inflammation: Change in Score</title>
        <description>Change from baseline in portal inflammation score. The amount of portal inflammation is based on central pathologist grading of liver biopsies: 0=none; 1=mild, 2=more than mild. Change in portal inflammation score has a possible range of -2 to +2, with negative values indicating a better outcome (improvement) and positive values indicating a worse outcome (no improvement).</description>
        <time_frame>52 weeks</time_frame>
        <population>The smaller number of participants analyzed is due to missing 52-week biopsies (complete case analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>DR Cysteamine Bitartrate Capsule</title>
            <description>Active DR cysteamine bitartrate capsule
DR cysteamine bitartrate capsule: ◦ 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline
750 mg/day (five 75 mg capsules twice daily) for patients &gt;65 - 80 kg at baseline
900 mg/day (six 75 mg capsules twice daily) for patients &gt;80 kg at baseline</description>
          </group>
          <group group_id="O2">
            <title>DR Cysteamine Bitartrate Placebo</title>
            <description>Placebo DR cysteamine bitartrate capsule
DR cysteamine bitartrate placebo: ◦ 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline
750 mg/day (five 75 mg capsules twice daily) for patients &gt;65 - 80 kg at baseline
900 mg/day (six 75 mg capsules twice daily) for patients &gt;80 kg at baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Portal Inflammation: Change in Score</title>
          <description>Change from baseline in portal inflammation score. The amount of portal inflammation is based on central pathologist grading of liver biopsies: 0=none; 1=mild, 2=more than mild. Change in portal inflammation score has a possible range of -2 to +2, with negative values indicating a better outcome (improvement) and positive values indicating a worse outcome (no improvement).</description>
          <population>The smaller number of participants analyzed is due to missing 52-week biopsies (complete case analysis).</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.6"/>
                    <measurement group_id="O2" value="-0.1" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>P-values and mean changes from baseline were calculated using ANCOVA, regressing change from baseline to 52 weeks on treatment group and baseline value of the outcome, for outcome scores.</non_inferiority_desc>
            <p_value>0.76</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2</ci_lower_limit>
            <ci_upper_limit>0.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fibrosis: Patients With Improvement</title>
        <description>Improvement in fibrosis stage defined as any decrease in fibrosis stage comparing 52-week biopsy to baseline.</description>
        <time_frame>52 weeks</time_frame>
        <population>Analysis based on intention to treat; patients with missing 52-week biopsy were imputed as lack of improvement.</population>
        <group_list>
          <group group_id="O1">
            <title>DR Cysteamine Bitartrate Capsule</title>
            <description>Active DR cysteamine bitartrate capsule
DR cysteamine bitartrate capsule: ◦ 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline
750 mg/day (five 75 mg capsules twice daily) for patients &gt;65 - 80 kg at baseline
900 mg/day (six 75 mg capsules twice daily) for patients &gt;80 kg at baseline</description>
          </group>
          <group group_id="O2">
            <title>DR Cysteamine Bitartrate Placebo</title>
            <description>Placebo DR cysteamine bitartrate capsule
DR cysteamine bitartrate placebo: ◦ 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline
750 mg/day (five 75 mg capsules twice daily) for patients &gt;65 - 80 kg at baseline
900 mg/day (six 75 mg capsules twice daily) for patients &gt;80 kg at baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Fibrosis: Patients With Improvement</title>
          <description>Improvement in fibrosis stage defined as any decrease in fibrosis stage comparing 52-week biopsy to baseline.</description>
          <population>Analysis based on intention to treat; patients with missing 52-week biopsy were imputed as lack of improvement.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Relative risks and p-values were calculated with the Cochran-Mantel-Haenszel chi-square tests, stratified by clinic and weight group, for binary outcomes.</non_inferiority_desc>
            <p_value>0.98</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.6</ci_lower_limit>
            <ci_upper_limit>1.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fibrosis: Change in Stage</title>
        <description>Change from baseline in fibrosis stage. The amount of fibrosis is based on central pathologist grading of liver biopsies: 0=none; 1a=mild, zone 3 perisinusoidal, 1b=moderate, zone 3, perisinusoidal, 1c=portal/periportal only, 2=zone 3 and periportal, any combination, 3=bridging, 4=cirrhosis. Fibrosis stages 1a, 1b, 1c recoded as 1, so the possible range of values for fibrosis stage was 0-4. Change in fibrosis stage has a possible range of -4 to +4, with negative values indicating a better outcome (improvement) and positive values indicating a worse outcome (no improvement).</description>
        <time_frame>52 weeks</time_frame>
        <population>The smaller number of participants analyzed is due to missing 52-week biopsies (complete case analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>DR Cysteamine Bitartrate Capsule</title>
            <description>Active DR cysteamine bitartrate capsule
DR cysteamine bitartrate capsule: ◦ 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline
750 mg/day (five 75 mg capsules twice daily) for patients &gt;65 - 80 kg at baseline
900 mg/day (six 75 mg capsules twice daily) for patients &gt;80 kg at baseline</description>
          </group>
          <group group_id="O2">
            <title>DR Cysteamine Bitartrate Placebo</title>
            <description>Placebo DR cysteamine bitartrate capsule
DR cysteamine bitartrate placebo: ◦ 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline
750 mg/day (five 75 mg capsules twice daily) for patients &gt;65 - 80 kg at baseline
900 mg/day (six 75 mg capsules twice daily) for patients &gt;80 kg at baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Fibrosis: Change in Stage</title>
          <description>Change from baseline in fibrosis stage. The amount of fibrosis is based on central pathologist grading of liver biopsies: 0=none; 1a=mild, zone 3 perisinusoidal, 1b=moderate, zone 3, perisinusoidal, 1c=portal/periportal only, 2=zone 3 and periportal, any combination, 3=bridging, 4=cirrhosis. Fibrosis stages 1a, 1b, 1c recoded as 1, so the possible range of values for fibrosis stage was 0-4. Change in fibrosis stage has a possible range of -4 to +4, with negative values indicating a better outcome (improvement) and positive values indicating a worse outcome (no improvement).</description>
          <population>The smaller number of participants analyzed is due to missing 52-week biopsies (complete case analysis).</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.9"/>
                    <measurement group_id="O2" value="-0.1" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>P-values and mean changes from baseline were calculated using ANCOVA, regressing change from baseline to 52 weeks on treatment group and baseline value of the outcome, for outcome scores.</non_inferiority_desc>
            <p_value>0.24</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>0.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Resolution of NASH</title>
        <description>Patients with a change from a histological diagnosis of definite NASH or indeterminate for NASH to not NASH at end of treatment</description>
        <time_frame>52 weeks</time_frame>
        <population>Analysis was limited to patients with a diagnosis of definite NASH at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>DR Cysteamine Bitartrate Capsule</title>
            <description>Active DR cysteamine bitartrate capsule
DR cysteamine bitartrate capsule: ◦ 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline
750 mg/day (five 75 mg capsules twice daily) for patients &gt;65 - 80 kg at baseline
900 mg/day (six 75 mg capsules twice daily) for patients &gt;80 kg at baseline</description>
          </group>
          <group group_id="O2">
            <title>DR Cysteamine Bitartrate Placebo</title>
            <description>Placebo DR cysteamine bitartrate capsule
DR cysteamine bitartrate placebo: ◦ 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline
750 mg/day (five 75 mg capsules twice daily) for patients &gt;65 - 80 kg at baseline
900 mg/day (six 75 mg capsules twice daily) for patients &gt;80 kg at baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Resolution of NASH</title>
          <description>Patients with a change from a histological diagnosis of definite NASH or indeterminate for NASH to not NASH at end of treatment</description>
          <population>Analysis was limited to patients with a diagnosis of definite NASH at baseline.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Relative risks and p-values were calculated with the Cochran-Mantel-Haenszel chi-square tests, stratified by clinic and weight group, for binary outcomes.</non_inferiority_desc>
            <p_value>0.29</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by clinic and weight group</method_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>2.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.4</ci_lower_limit>
            <ci_upper_limit>18.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Aminotransferase and Gamma-glutamyl Transpeptidase</title>
        <time_frame>52 weeks</time_frame>
        <population>The smaller number of participants analyzed is due to missing 52-week laboratory data.</population>
        <group_list>
          <group group_id="O1">
            <title>DR Cysteamine Bitartrate Capsule</title>
            <description>Active DR cysteamine bitartrate capsule
DR cysteamine bitartrate capsule: ◦ 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline
750 mg/day (five 75 mg capsules twice daily) for patients &gt;65 - 80 kg at baseline
900 mg/day (six 75 mg capsules twice daily) for patients &gt;80 kg at baseline</description>
          </group>
          <group group_id="O2">
            <title>DR Cysteamine Bitartrate Placebo</title>
            <description>Placebo DR cysteamine bitartrate capsule
DR cysteamine bitartrate placebo: ◦ 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline
750 mg/day (five 75 mg capsules twice daily) for patients &gt;65 - 80 kg at baseline
900 mg/day (six 75 mg capsules twice daily) for patients &gt;80 kg at baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Aminotransferase and Gamma-glutamyl Transpeptidase</title>
          <population>The smaller number of participants analyzed is due to missing 52-week laboratory data.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Alanine aminotransferase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-53" spread="88"/>
                    <measurement group_id="O2" value="-8" spread="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate aminotransferase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31" spread="52"/>
                    <measurement group_id="O2" value="-4" spread="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gamma-glutamyl transpeptidase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10" spread="23"/>
                    <measurement group_id="O2" value="-1" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted difference in mean changes in serum alanine aminotransferase (ALT). The change in ALT is adjusted for the baseline ALT value; therefore, the adjusted difference in mean changes is not equal to the net change.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>P-value and difference in mean changes from baseline were calculated using ANCOVA models, regressing change from baseline to 52 weeks in serum alanine aminotransferase on treatment group and baseline value of serum alanine aminotransferase.</non_inferiority_desc>
            <p_value>0.02</p_value>
            <method>ANCOVA</method>
            <method_desc>Adjusted for baseline serum alanine aminotransferase</method_desc>
            <param_type>Adjusted difference in mean changes</param_type>
            <param_value>-24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-44</ci_lower_limit>
            <ci_upper_limit>-4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted difference in mean changes in serum aspartate aminotransferase (AST). The change in AST is adjusted for the baseline AST value; therefore, the adjusted difference in mean changes is not equal to the net change.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>P-value and difference in mean changes from baseline were calculated using ANCOVA models, regressing changes from baseline to 52 weeks in serum aspartate aminotransferase on treatment group and baseline value of serum aspartate aminotransferase.</non_inferiority_desc>
            <p_value>0.008</p_value>
            <method>ANCOVA</method>
            <method_desc>Adjusted for baseline serum aspartate aminotransferase.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-26</ci_lower_limit>
            <ci_upper_limit>-4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted difference in mean changes in serum gamma-glutamyl transpeptidase (GGT). The change in GGT is adjusted for the baseline GGTvalue; therefore, the adjusted difference in mean changes is not equal to the net change.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>P-value and difference in mean changes from baseline were calculated using ANCOVA models, regressing changes from baseline to 52 weeks in gamma-glutamyl transpeptidase on treatment group and baseline value of gamma-glutamyl transpeptidase.</non_inferiority_desc>
            <p_value>0.02</p_value>
            <method>ANCOVA</method>
            <method_desc>Adjusted for baseline gamma-glutamyl transpeptidase</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13</ci_lower_limit>
            <ci_upper_limit>-1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Weight (kg)</title>
        <time_frame>52 weeks</time_frame>
        <population>Smaller number of patients analyzed due to missing 52-week weight measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>DR Cysteamine Bitartrate Capsule</title>
            <description>Active DR cysteamine bitartrate capsule
DR cysteamine bitartrate capsule: ◦ 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline
750 mg/day (five 75 mg capsules twice daily) for patients &gt;65 - 80 kg at baseline
900 mg/day (six 75 mg capsules twice daily) for patients &gt;80 kg at baseline</description>
          </group>
          <group group_id="O2">
            <title>DR Cysteamine Bitartrate Placebo</title>
            <description>Placebo DR cysteamine bitartrate capsule
DR cysteamine bitartrate placebo: ◦ 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline
750 mg/day (five 75 mg capsules twice daily) for patients &gt;65 - 80 kg at baseline
900 mg/day (six 75 mg capsules twice daily) for patients &gt;80 kg at baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Weight (kg)</title>
          <population>Smaller number of patients analyzed due to missing 52-week weight measurement.</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" spread="9.3"/>
                    <measurement group_id="O2" value="7.8" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted difference in mean changes in weight (kg). The change in weight is adjusted for the baseline weight value; therefore, the adjusted difference in mean changes is not equal to the net change.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>P-value and adjusted difference in mean changes from baseline were calculated using ANCOVA models, regressing changes from baseline to 52 weeks in weight (kg) on treatment group and baseline weight (kg).</non_inferiority_desc>
            <p_value>0.25</p_value>
            <method>ANCOVA</method>
            <method_desc>Adjusted for baseline weight (kg).</method_desc>
            <param_type>Adjusted difference in mean changes</param_type>
            <param_value>-1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.1</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Body-mass Index</title>
        <time_frame>52 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DR Cysteamine Bitartrate Capsule</title>
            <description>Active DR cysteamine bitartrate capsule
DR cysteamine bitartrate capsule: ◦ 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline
750 mg/day (five 75 mg capsules twice daily) for patients &gt;65 - 80 kg at baseline
900 mg/day (six 75 mg capsules twice daily) for patients &gt;80 kg at baseline</description>
          </group>
          <group group_id="O2">
            <title>DR Cysteamine Bitartrate Placebo</title>
            <description>Placebo DR cysteamine bitartrate capsule
DR cysteamine bitartrate placebo: ◦ 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline
750 mg/day (five 75 mg capsules twice daily) for patients &gt;65 - 80 kg at baseline
900 mg/day (six 75 mg capsules twice daily) for patients &gt;80 kg at baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Body-mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="2.8"/>
                    <measurement group_id="O2" value="1.1" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted difference in mean changes in body mass index (BMI). The change in BMI is adjusted for the baseline BMI value; therefore, the adjusted difference in mean changes is not equal to the net change.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>P-values and differences in mean changes from baseline were calculated using ANCOVA models, regressing changes from baseline to 52 weeks on treatment group and baseline value of the outcome.</non_inferiority_desc>
            <p_value>0.42</p_value>
            <method>ANCOVA</method>
            <method_desc>Adjusted for baseline BMI (kg/m2)</method_desc>
            <param_type>Adjusted difference in mean changes</param_type>
            <param_value>-0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.1</ci_lower_limit>
            <ci_upper_limit>0.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Body-mass Index Z-score</title>
        <time_frame>52 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DR Cysteamine Bitartrate Capsule</title>
            <description>Active DR cysteamine bitartrate capsule
DR cysteamine bitartrate capsule: ◦ 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline
750 mg/day (five 75 mg capsules twice daily) for patients &gt;65 - 80 kg at baseline
900 mg/day (six 75 mg capsules twice daily) for patients &gt;80 kg at baseline</description>
          </group>
          <group group_id="O2">
            <title>DR Cysteamine Bitartrate Placebo</title>
            <description>Placebo DR cysteamine bitartrate capsule
DR cysteamine bitartrate placebo: ◦ 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline
750 mg/day (five 75 mg capsules twice daily) for patients &gt;65 - 80 kg at baseline
900 mg/day (six 75 mg capsules twice daily) for patients &gt;80 kg at baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Body-mass Index Z-score</title>
          <units>SD</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.3"/>
                    <measurement group_id="O2" value="0" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>P-values and differences in mean changes from baseline were calculated using ANCOVA models, regressing changes from baseline to 52 weeks on treatment group and baseline value of the outcome.</non_inferiority_desc>
            <p_value>0.11</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1</ci_lower_limit>
            <ci_upper_limit>0.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Waist Circumference</title>
        <time_frame>52 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DR Cysteamine Bitartrate Capsule</title>
            <description>Active DR cysteamine bitartrate capsule
DR cysteamine bitartrate capsule: ◦ 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline
750 mg/day (five 75 mg capsules twice daily) for patients &gt;65 - 80 kg at baseline
900 mg/day (six 75 mg capsules twice daily) for patients &gt;80 kg at baseline</description>
          </group>
          <group group_id="O2">
            <title>DR Cysteamine Bitartrate Placebo</title>
            <description>Placebo DR cysteamine bitartrate capsule
DR cysteamine bitartrate placebo: ◦ 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline
750 mg/day (five 75 mg capsules twice daily) for patients &gt;65 - 80 kg at baseline
900 mg/day (six 75 mg capsules twice daily) for patients &gt;80 kg at baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Waist Circumference</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="7.7"/>
                    <measurement group_id="O2" value="2.3" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted difference in mean changes in waist circumference (cm). The change in waist circumference is adjusted for the baseline waist circumference value; therefore, the adjusted difference in mean changes is not equal to the net change.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>P-values and differences in mean changes from baseline were calculated using ANCOVA models, regressing changes from baseline to 52 weeks in waist circumference on treatment group and baseline value of waist circumference.</non_inferiority_desc>
            <p_value>0.89</p_value>
            <method>ANCOVA</method>
            <method_desc>Adjusted for baseline waist circumference (cm)</method_desc>
            <param_type>Adjusted difference in mean changes</param_type>
            <param_value>0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.3</ci_lower_limit>
            <ci_upper_limit>2.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Serum Glucose</title>
        <time_frame>52 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DR Cysteamine Bitartrate Capsule</title>
            <description>Active DR cysteamine bitartrate capsule
DR cysteamine bitartrate capsule: ◦ 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline
750 mg/day (five 75 mg capsules twice daily) for patients &gt;65 - 80 kg at baseline
900 mg/day (six 75 mg capsules twice daily) for patients &gt;80 kg at baseline</description>
          </group>
          <group group_id="O2">
            <title>DR Cysteamine Bitartrate Placebo</title>
            <description>Placebo DR cysteamine bitartrate capsule
DR cysteamine bitartrate placebo: ◦ 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline
750 mg/day (five 75 mg capsules twice daily) for patients &gt;65 - 80 kg at baseline
900 mg/day (six 75 mg capsules twice daily) for patients &gt;80 kg at baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Serum Glucose</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="12"/>
                    <measurement group_id="O2" value="5" spread="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted difference in mean changes in fasting serum glucose. The change in fasting serum glucose is adjusted for the baseline fasting serum glucose value; therefore, the adjusted difference in mean changes is not equal to the net change.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>P-values and differences in mean changes from baseline were calculated using ANCOVA models, regressing changes from baseline to 52 weeks in fasting serum glucose on treatment group and baseline fasting serum glucose value.</non_inferiority_desc>
            <p_value>0.24</p_value>
            <method>ANCOVA</method>
            <method_desc>Adjusted for baseline serum glucose value.</method_desc>
            <param_type>Adjusted difference in mean changes</param_type>
            <param_value>-4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11</ci_lower_limit>
            <ci_upper_limit>3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Insulin</title>
        <time_frame>52 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DR Cysteamine Bitartrate Capsule</title>
            <description>Active DR cysteamine bitartrate capsule
DR cysteamine bitartrate capsule: ◦ 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline
750 mg/day (five 75 mg capsules twice daily) for patients &gt;65 - 80 kg at baseline
900 mg/day (six 75 mg capsules twice daily) for patients &gt;80 kg at baseline</description>
          </group>
          <group group_id="O2">
            <title>DR Cysteamine Bitartrate Placebo</title>
            <description>Placebo DR cysteamine bitartrate capsule
DR cysteamine bitartrate placebo: ◦ 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline
750 mg/day (five 75 mg capsules twice daily) for patients &gt;65 - 80 kg at baseline
900 mg/day (six 75 mg capsules twice daily) for patients &gt;80 kg at baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Insulin</title>
          <units>μU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" spread="36"/>
                    <measurement group_id="O2" value="10" spread="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted difference in mean changes in fasting insulin. The change in fasting insulin is adjusted for the baseline fasting insulin value; therefore, the adjusted difference in mean changes is not equal to the net change.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>P-value and difference in mean changes from baseline were calculated using ANCOVA models, regressing changes from baseline to 52 weeks in fasting insulin on treatment group and baseline fasting insulin.</non_inferiority_desc>
            <p_value>0.34</p_value>
            <method>ANCOVA</method>
            <method_desc>Adjusted for baseline fasting insulin.</method_desc>
            <param_type>Adjusted difference in mean changes</param_type>
            <param_value>-6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18</ci_lower_limit>
            <ci_upper_limit>6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in HOMA-IR</title>
        <description>(Glucose (mmol/L) x insulin (pmol/L))/22.5</description>
        <time_frame>52 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DR Cysteamine Bitartrate Capsule</title>
            <description>Active DR cysteamine bitartrate capsule
DR cysteamine bitartrate capsule: ◦ 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline
750 mg/day (five 75 mg capsules twice daily) for patients &gt;65 - 80 kg at baseline
900 mg/day (six 75 mg capsules twice daily) for patients &gt;80 kg at baseline</description>
          </group>
          <group group_id="O2">
            <title>DR Cysteamine Bitartrate Placebo</title>
            <description>Placebo DR cysteamine bitartrate capsule
DR cysteamine bitartrate placebo: ◦ 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline
750 mg/day (five 75 mg capsules twice daily) for patients &gt;65 - 80 kg at baseline
900 mg/day (six 75 mg capsules twice daily) for patients &gt;80 kg at baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HOMA-IR</title>
          <description>(Glucose (mmol/L) x insulin (pmol/L))/22.5</description>
          <units>(10E-15 mol^2)/L^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="9.2"/>
                    <measurement group_id="O2" value="3.6" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted difference in mean changes in HOMA-IR. The change in HOMA-IR is adjusted for the baseline HOMA-IR value; therefore, the adjusted difference in mean changes is not equal to the net change.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>P-values and differences in mean changes from baseline were calculated using ANCOVA models, regressing changes from baseline to 52 weeks in HOMA-IR on treatment group and baseline HOMA-IR value.</non_inferiority_desc>
            <p_value>0.15</p_value>
            <method>ANCOVA</method>
            <method_desc>Adjusted for baseline HOMA-IR.</method_desc>
            <param_type>Adjusted difference in mean changes</param_type>
            <param_value>-2.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.2</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Systolic Blood Pressure</title>
        <time_frame>52 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DR Cysteamine Bitartrate Capsule</title>
            <description>Active DR cysteamine bitartrate capsule
DR cysteamine bitartrate capsule: ◦ 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline
750 mg/day (five 75 mg capsules twice daily) for patients &gt;65 - 80 kg at baseline
900 mg/day (six 75 mg capsules twice daily) for patients &gt;80 kg at baseline</description>
          </group>
          <group group_id="O2">
            <title>DR Cysteamine Bitartrate Placebo</title>
            <description>Placebo DR cysteamine bitartrate capsule
DR cysteamine bitartrate placebo: ◦ 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline
750 mg/day (five 75 mg capsules twice daily) for patients &gt;65 - 80 kg at baseline
900 mg/day (six 75 mg capsules twice daily) for patients &gt;80 kg at baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Systolic Blood Pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" spread="12"/>
                    <measurement group_id="O2" value="2" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted difference in mean changes in systolic blood pressure. The change in systolic blood pressure is adjusted for the baseline systolic blood pressure value; therefore, the adjusted difference in mean changes is not equal to the net change.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>P-values and differences in mean changes from baseline were calculated using ANCOVA models, regressing changes from baseline to 52 weeks in systolic blood pressure on treatment group and baseline systolic blood pressure value.</non_inferiority_desc>
            <p_value>0.71</p_value>
            <method>ANCOVA</method>
            <method_desc>Adjusted for baseline systolic blood pressure.</method_desc>
            <param_type>Adjusted difference in mean changes</param_type>
            <param_value>1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3</ci_lower_limit>
            <ci_upper_limit>4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Diastolic Blood Pressure</title>
        <time_frame>52 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DR Cysteamine Bitartrate Capsule</title>
            <description>Active DR cysteamine bitartrate capsule
DR cysteamine bitartrate capsule: ◦ 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline
750 mg/day (five 75 mg capsules twice daily) for patients &gt;65 - 80 kg at baseline
900 mg/day (six 75 mg capsules twice daily) for patients &gt;80 kg at baseline</description>
          </group>
          <group group_id="O2">
            <title>DR Cysteamine Bitartrate Placebo</title>
            <description>Placebo DR cysteamine bitartrate capsule
DR cysteamine bitartrate placebo: ◦ 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline
750 mg/day (five 75 mg capsules twice daily) for patients &gt;65 - 80 kg at baseline
900 mg/day (six 75 mg capsules twice daily) for patients &gt;80 kg at baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Diastolic Blood Pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" spread="9"/>
                    <measurement group_id="O2" value="1" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted difference in mean changes in diastolic blood pressure. The change in diastolic blood pressure is adjusted for the baseline diastolic blood pressure value; therefore, the adjusted difference in mean changes is not equal to the net change.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>P-values and differences in mean changes from baseline were calculated using ANCOVA models, regressing changes from baseline to 52 weeks in diastolic blood pressure on treatment group and baseline diastolic blood pressure value.</non_inferiority_desc>
            <p_value>0.31</p_value>
            <method>ANCOVA</method>
            <method_desc>Adjusted for baseline diastolic blood pressure.</method_desc>
            <param_type>Adjusted difference in mean changes</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4</ci_lower_limit>
            <ci_upper_limit>1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Pediatric Quality of Life Inventory (PedsQL) Score</title>
        <description>Pediatric Quality of Life Inventory (PedsQL) version 4.0 is completed by both the child and parent/caregiver, and is composed of 23 items comprising 4 dimensions: Physical Functioning, Emotional Functioning, Social Functioning, and School Functioning. Scores are transformed on a scale from 0 to 100, with higher scores indicating better health-related quality of life. Physical Health Summary Score =Physical Functioning Scale Score. Psychosocial Health Summary Score = Sum of items over the number of items answered in the Emotional, Social, and School Functioning Scales.</description>
        <time_frame>52 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DR Cysteamine Bitartrate Capsule</title>
            <description>Active DR cysteamine bitartrate capsule
DR cysteamine bitartrate capsule: ◦ 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline
750 mg/day (five 75 mg capsules twice daily) for patients &gt;65 - 80 kg at baseline
900 mg/day (six 75 mg capsules twice daily) for patients &gt;80 kg at baseline</description>
          </group>
          <group group_id="O2">
            <title>DR Cysteamine Bitartrate Placebo</title>
            <description>Placebo DR cysteamine bitartrate capsule
DR cysteamine bitartrate placebo: ◦ 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline
750 mg/day (five 75 mg capsules twice daily) for patients &gt;65 - 80 kg at baseline
900 mg/day (six 75 mg capsules twice daily) for patients &gt;80 kg at baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pediatric Quality of Life Inventory (PedsQL) Score</title>
          <description>Pediatric Quality of Life Inventory (PedsQL) version 4.0 is completed by both the child and parent/caregiver, and is composed of 23 items comprising 4 dimensions: Physical Functioning, Emotional Functioning, Social Functioning, and School Functioning. Scores are transformed on a scale from 0 to 100, with higher scores indicating better health-related quality of life. Physical Health Summary Score =Physical Functioning Scale Score. Psychosocial Health Summary Score = Sum of items over the number of items answered in the Emotional, Social, and School Functioning Scales.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Self-reported physical health</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" spread="17"/>
                    <measurement group_id="O2" value="5" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Self-reported psychosocial health</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" spread="15"/>
                    <measurement group_id="O2" value="5" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parent/guardian-reported physical health</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" spread="27"/>
                    <measurement group_id="O2" value="5" spread="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parent/guardian-reported psychosocial health</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" spread="18"/>
                    <measurement group_id="O2" value="6" spread="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted difference in mean changes from baseline in self-reported Physical Health summary score from the Pediatric Quality of Life Inventory (PedsQL). The difference in mean changes in Physical Health summary score is adjusted for the baseline Physical Health summary score; therefore, the adjusted difference in mean changes is not equal to the net change. Higher scores indicate better health-related quality of life.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>P-value and difference in mean changes from baseline were calculated using ANCOVA models, regressing changes from baseline to 52 weeks in self-reported Physical Health summary score on treatment group and baseline value of the Physical Health summary score.</non_inferiority_desc>
            <p_value>0.77</p_value>
            <method>ANCOVA</method>
            <method_desc>Adjusted for baseline self-reported Physical Health summary score.</method_desc>
            <param_type>Adjusted difference in mean changes</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5</ci_lower_limit>
            <ci_upper_limit>3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted difference in mean changes from baseline in self-reported Psychosocial Health summary score from the Pediatric Quality of Life Inventory (PedsQL). The difference in mean changes in Psychosocial Health summary score is adjusted for the baseline Psychosocial Health summary score; therefore, the adjusted difference in mean changes is not equal to the net change. Higher scores indicate better health-related quality of life.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>P-value and difference in mean changes from baseline were calculated using ANCOVA models, regressing changes from baseline to 52 weeks in Pyschosocial Health summary score on treatment group and baseline Psychosocial Health summary score.</non_inferiority_desc>
            <p_value>0.64</p_value>
            <method>ANCOVA</method>
            <method_desc>Adjusted for baseline Psychosocial Health summary score.</method_desc>
            <param_type>Adjusted difference in mean changes</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5</ci_lower_limit>
            <ci_upper_limit>3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted difference in mean changes from baseline in parent/guardian-reported Physical Health summary score from the Pediatric Quality of Life Inventory (PedsQL). The difference in mean changes in parent/guardian-reported Physical Health summary score is adjusted for the baseline parent/guardian-reported Physical Health summary score; therefore, the adjusted difference in mean changes is not equal to the net change. Higher scores indicate better health-related quality of life.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>P-value and difference in mean changes from baseline were calculated using ANCOVA models, regressing changes from baseline to 52 weeks in parent/guardian-reported Physical Health summary score on treatment group and baseline value of the parent/guardian-reported Physical Health summary score.</non_inferiority_desc>
            <p_value>0.58</p_value>
            <method>ANCOVA</method>
            <method_desc>Adjusted for baseline parent/guardian-reported Physical Health summary score.</method_desc>
            <param_type>Adjusted difference in mean changes</param_type>
            <param_value>-2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9</ci_lower_limit>
            <ci_upper_limit>5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted difference in mean changes from baseline in parent/guardian-reported Psychosocial Health summary score from the Pediatric Quality of Life Inventory (PedsQL). The difference in mean changes in parent/guardian-reported Psychosocial Health summary score is adjusted for the baseline parent/guardian-reported Psychosocial Health summary score; therefore, the adjusted difference in mean changes is not equal to the net change. Higher scores indicate better health-related quality of life.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>P-value and difference in mean changes from baseline were calculated using ANCOVA models, regressing changes from baseline to 52 weeks in parent/guardian-reported Psychosocial Health summary score on treatment group and baseline value of the parent/guardian-reported Psychosocial Health summary score.</non_inferiority_desc>
            <p_value>0.85</p_value>
            <method>ANCOVA</method>
            <param_type>Adjusted difference in mean changes</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6</ci_lower_limit>
            <ci_upper_limit>5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reduction in MRI-determined Hepatic Fat Fraction</title>
        <description>Change from baseline in MRI Proton Density Fat Fraction (PDFF) (%).</description>
        <time_frame>52 weeks</time_frame>
        <population>The smaller number of observations is because MRI was an optional procedure. This is the number with MRI exams at both baseline and 52 weeks.</population>
        <group_list>
          <group group_id="O1">
            <title>DR Cysteamine Bitartrate Capsule</title>
            <description>Active DR cysteamine bitartrate capsule
DR cysteamine bitartrate capsule: ◦ 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline
750 mg/day (five 75 mg capsules twice daily) for patients &gt;65 - 80 kg at baseline
900 mg/day (six 75 mg capsules twice daily) for patients &gt;80 kg at baseline</description>
          </group>
          <group group_id="O2">
            <title>DR Cysteamine Bitartrate Placebo</title>
            <description>Placebo DR cysteamine bitartrate capsule
DR cysteamine bitartrate placebo: ◦ 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline
750 mg/day (five 75 mg capsules twice daily) for patients &gt;65 - 80 kg at baseline
900 mg/day (six 75 mg capsules twice daily) for patients &gt;80 kg at baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Reduction in MRI-determined Hepatic Fat Fraction</title>
          <description>Change from baseline in MRI Proton Density Fat Fraction (PDFF) (%).</description>
          <population>The smaller number of observations is because MRI was an optional procedure. This is the number with MRI exams at both baseline and 52 weeks.</population>
          <units>percentage of PDFF</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.3" spread="7.1"/>
                    <measurement group_id="O2" value="-2.6" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.11</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.7</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>52 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>DR Cysteamine Bitartrate Capsule</title>
          <description>Active DR cysteamine bitartrate capsule
DR cysteamine bitartrate capsule: ◦ 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline
750 mg/day (five 75 mg capsules twice daily) for patients &gt;65 - 80 kg at baseline
900 mg/day (six 75 mg capsules twice daily) for patients &gt;80 kg at baseline</description>
        </group>
        <group group_id="E2">
          <title>DR Cysteamine Bitartrate Placebo</title>
          <description>Placebo DR cysteamine bitartrate capsule
DR cysteamine bitartrate placebo: ◦ 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline
750 mg/day (five 75 mg capsules twice daily) for patients &gt;65 - 80 kg at baseline
900 mg/day (six 75 mg capsules twice daily) for patients &gt;80 kg at baseline</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pain - Abdomen NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Pain - Gallbladder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection - Appendix</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Soft tissue necrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mood alteration - depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Personality/behavioral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Pain - middle ear</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Metabolic/lab - other</sub_title>
                <description>Decrease in hemoglobin</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Metabolic/lab - other</sub_title>
                <description>Worsening insulin resistance</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular - other</sub_title>
                <description>Change in prescription</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Ocular surface disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Ocular - other</sub_title>
                <description>Periorbital cellulitis</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Ocular - other (eye redness, allergies)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pain - abdomen NOS</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="88"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="88"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Teeth</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="88"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="88"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Pain - stomach</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="88"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="88"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI - rectum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Heartburn</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage - pulmonary - nose</sub_title>
                <description>Nosebleed</description>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="88"/>
                <counts group_id="E2" events="8" subjects_affected="4" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Flu-like syndrome</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolic/lab - other</sub_title>
                <description>Increase in ALT and AST</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="88"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Allergy - other</sub_title>
                <description>Cat allergy</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection - skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Infection - urinary tract NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Infection - ungual</sub_title>
                <description>Nail infection</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Infection - pharynx</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Infection - larynx</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Infection - stomach</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Infection - middle ear (otitis media)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="88"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Infection (middle ear) with unknown ANC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Infection (ungual) with unknown ANC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Infection (sinus) with unknown ANC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Infection - upper airway NOS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="88"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Infection - bronchus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Infection - sinus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Infection (documented clinically) - pharynx</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Infection - lung (pneumonia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Pain - bone</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Neurology - other (concussion)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Intraop injury - liver</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Dermatology - other</sub_title>
                <description>Stepped on nail</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Musculoskeletal - other (ankle sprain)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Musculoskeletal - other (wrist sprain)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Musculoskeletal - other (finger sprain)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Cervical spine ROM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertriglyceridemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Pain - joint</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Bone growth - spine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Extremity - upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Joint - function</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Lumbar spine ROM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Pain (extremity - limb)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="88"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Joint - function</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Musculoskletal - other (spondylosis)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Pain - head/headache</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="88"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Neuropathy - sensory</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mood alteration - anxiety</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Mood alteration - not specified</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Mood alteration - depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Mood alteration - irritability</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pain - testicle</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Pain - breast</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GU - vaginal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Gynecomastia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Irregular menses</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="88"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Pain - chest/thorax NOS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="88"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Nasal/paranasal reactions</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Pain - chest wall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Pulmonary - other (cold)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="88"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Pulmonary - other</sub_title>
                <description>Positive PPD, negative chest X-ray</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Pain - throat/pharynx/larynx</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="88"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Striae</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Hyperpigmentation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Hypopigmentation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Pain - skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Ulceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Dermatology - other</sub_title>
                <description>Edematous nodular lesions with pruritus</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Dermatology - other (warts, HPV)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Sexual - other (orchiopexy)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Tonsillectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vasculitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Laura Wilson</name_or_title>
      <organization>Johns Hopkins Data Coordinating Center</organization>
      <phone>410-955-0719</phone>
      <email>lwilson9@jhu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

